News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The move will add new global talent to Cytel’s Strategic Consulting group
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
The Bulk Drug Park is expected to attract investment of around Rs. 10,000 crore and provide employment to more than 20,000 people
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Plans to double its manufacturing footprint to bolster the growth
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
Subscribe To Our Newsletter & Stay Updated
